8-KMaterial AgreementsExhibits & Filings

Edwards Lifesciences Corp 8-K Report, Material Agreement (Jun 6, 2005)

Filed June 6, 2005For Securities:EW

Summary

Edwards Lifesciences Corporation (EW) reported on June 6, 2005, that its wholly-owned subsidiary, Edwards Lifesciences PVT, Inc., entered into several definitive agreements with 3F Therapeutics, Inc. on June 2, 2005. These agreements, collectively referred to as the Transaction Agreements, aim to resolve prior disputes and establish new licensing and supply arrangements. The primary financial impact for investors is the settlement payment of $24.75 million to 3F Therapeutics, intended to terminate existing development and supply agreements. This payment signifies a resolution of past issues and a strategic step to move forward with new arrangements. The agreements also include co-exclusive and non-exclusive license grants between the entities, with potential for future royalty revenue for Edwards Lifesciences.

Key Highlights

  • 1Edwards Lifesciences PVT, Inc. entered into a Master Agreement, Supply and Training Agreement, Co-Exclusive License Agreement, and Non-Exclusive License Agreement with 3F Therapeutics, Inc. on June 2, 2005.
  • 2The Master Agreement terminates previous development and supply agreements and includes a mutual release of liability, except for certain exceptions.
  • 3Edwards Lifesciences will pay a total of $24.75 million to 3F Therapeutics to settle these prior agreements, with $22.75 million paid on the effective date and $2 million contingent on the termination of the Supply and Training Agreement.
  • 4A separate payment of $250,000 was made for a non-exclusive license from 3F Therapeutics.
  • 5Edwards Lifesciences granted 3F Therapeutics co-exclusive, royalty-bearing licenses under certain company patents, with 3F Therapeutics obligated to pay a 4% royalty on net sales of licensed products.
  • 63F Therapeutics granted Edwards Lifesciences royalty-free non-exclusive licenses under its patents and know-how.
  • 7The filing includes the full text of these Transaction Agreements as exhibits.

Frequently Asked Questions

Edwards Lifesciences will pay a total of $24.75 million to 3F Therapeutics to settle prior agreements. This is a significant cash outflow. However, the company also stands to receive royalty payments from 3F Therapeutics on sales of licensed products, which could provide future revenue.

The Transaction Agreements serve to terminate and resolve disputes related to previous development and supply agreements between Edwards Lifesciences (or its predecessor) and 3F Therapeutics. They also establish new co-exclusive and non-exclusive licensing arrangements and supply/training provisions.

Yes, under the Co-Exclusive License Agreement, Edwards Lifesciences has granted licenses to 3F Therapeutics and is entitled to receive a 4% royalty on the net sales of any licensed products sold by 3F Therapeutics in the specified fields of use.

Prior to these agreements, there were existing development and supply agreements between the two companies. The Master Agreement indicates that these prior agreements are being terminated, suggesting potential disagreements or a strategic shift that necessitated this settlement.